User login
Botox Cosmetic
Allergan, Inc, obtains US Food and Drug Administration approval of Botox Cosmetic (onabotulinumtoxinA) for temporary improvement of moderate to severe lateral canthal lines (crow’s-feet) in adults. It blocks nerve impulses and reduces muscle movements around the eyes. This indication will allow physicians to treat both crow’s-feet and frown lines (approved in 2002 for this latter indication) with little downtime for patients. For more information, visit www.allergan.com.
Fabior Foam 0.1%
Stiefel, a GSK company, receives US Food and Drug Administration approval of Fabior (tazarotene) Foam 0.1% for the treatment of acne vulgaris in patients 12 years and older. Fabior Foam is applied once daily before bedtime. For more information, visit www.fabiorfoam.com.
NIA24 Intensive Retinol Repair
Niadyne, Inc, introduces NIA24 Intensive Retinol Repair for photodamage. It targets the major signs of UV damage including wrinkles, hyperpigmentation, lack of firmness, and uneven texture and tone. Formulated with ProNiacin and retinol, NIA24 Intensive Retinol Repair strengthens the skin barrier and increases collagen. It is an alternative for patients who cannot tolerate retinoic acid or traditional retinol treatments. A prescription is not required, and it can be applied daily. For more information, visit www.NIA24.com.
Stelara
Janssen Biotech Inc obtains US Food and Drug Administration approval of Stelara (ustekinumab) to treat patients with active psoriatic arthritis, alone or in combination with methotrexate. Stelara targets the cytokines IL-12 and IL-23 to control joint pain, swelling, and stiffness associated with psoriatic arthritis, in addition to psoriasis plaque thickness, scaling, and redness. Stelara is administered every 12 weeks after 2 starter doses for the treatment of psoriatic arthritis. For more information, visit www.stelarainfo.com.
XTRAC Velocity 7
PhotoMedex Inc introduces XTRAC Velocity 7 with an advanced user interface for psoriasis and vitiligo. Using UVB light, the XTRAC excimer laser treats areas of the skin affected by psoriasis or vitiligo without harming the surrounding tissue. XTRAC Velocity 7 offers increased efficiency, with the rate of output increasing the speed for delivery of treatment. Treatment guidelines and suggestions based on body area are provided using the touch screen. It can be used on hard-to-reach areas such as the elbows, knees, and scalp. Before and after photographs can be stored to show progression of resolution, enhancing patient compliance. The manufacturer also offers a patient advocacy program for patients to call and obtain answers to product and insurance questions from a live operator; patients also can book appointments with a participating physician faster using the XTRAC TeleCare Center. For more information, visit www.xtracnow.com
Botox Cosmetic
Allergan, Inc, obtains US Food and Drug Administration approval of Botox Cosmetic (onabotulinumtoxinA) for temporary improvement of moderate to severe lateral canthal lines (crow’s-feet) in adults. It blocks nerve impulses and reduces muscle movements around the eyes. This indication will allow physicians to treat both crow’s-feet and frown lines (approved in 2002 for this latter indication) with little downtime for patients. For more information, visit www.allergan.com.
Fabior Foam 0.1%
Stiefel, a GSK company, receives US Food and Drug Administration approval of Fabior (tazarotene) Foam 0.1% for the treatment of acne vulgaris in patients 12 years and older. Fabior Foam is applied once daily before bedtime. For more information, visit www.fabiorfoam.com.
NIA24 Intensive Retinol Repair
Niadyne, Inc, introduces NIA24 Intensive Retinol Repair for photodamage. It targets the major signs of UV damage including wrinkles, hyperpigmentation, lack of firmness, and uneven texture and tone. Formulated with ProNiacin and retinol, NIA24 Intensive Retinol Repair strengthens the skin barrier and increases collagen. It is an alternative for patients who cannot tolerate retinoic acid or traditional retinol treatments. A prescription is not required, and it can be applied daily. For more information, visit www.NIA24.com.
Stelara
Janssen Biotech Inc obtains US Food and Drug Administration approval of Stelara (ustekinumab) to treat patients with active psoriatic arthritis, alone or in combination with methotrexate. Stelara targets the cytokines IL-12 and IL-23 to control joint pain, swelling, and stiffness associated with psoriatic arthritis, in addition to psoriasis plaque thickness, scaling, and redness. Stelara is administered every 12 weeks after 2 starter doses for the treatment of psoriatic arthritis. For more information, visit www.stelarainfo.com.
XTRAC Velocity 7
PhotoMedex Inc introduces XTRAC Velocity 7 with an advanced user interface for psoriasis and vitiligo. Using UVB light, the XTRAC excimer laser treats areas of the skin affected by psoriasis or vitiligo without harming the surrounding tissue. XTRAC Velocity 7 offers increased efficiency, with the rate of output increasing the speed for delivery of treatment. Treatment guidelines and suggestions based on body area are provided using the touch screen. It can be used on hard-to-reach areas such as the elbows, knees, and scalp. Before and after photographs can be stored to show progression of resolution, enhancing patient compliance. The manufacturer also offers a patient advocacy program for patients to call and obtain answers to product and insurance questions from a live operator; patients also can book appointments with a participating physician faster using the XTRAC TeleCare Center. For more information, visit www.xtracnow.com
Botox Cosmetic
Allergan, Inc, obtains US Food and Drug Administration approval of Botox Cosmetic (onabotulinumtoxinA) for temporary improvement of moderate to severe lateral canthal lines (crow’s-feet) in adults. It blocks nerve impulses and reduces muscle movements around the eyes. This indication will allow physicians to treat both crow’s-feet and frown lines (approved in 2002 for this latter indication) with little downtime for patients. For more information, visit www.allergan.com.
Fabior Foam 0.1%
Stiefel, a GSK company, receives US Food and Drug Administration approval of Fabior (tazarotene) Foam 0.1% for the treatment of acne vulgaris in patients 12 years and older. Fabior Foam is applied once daily before bedtime. For more information, visit www.fabiorfoam.com.
NIA24 Intensive Retinol Repair
Niadyne, Inc, introduces NIA24 Intensive Retinol Repair for photodamage. It targets the major signs of UV damage including wrinkles, hyperpigmentation, lack of firmness, and uneven texture and tone. Formulated with ProNiacin and retinol, NIA24 Intensive Retinol Repair strengthens the skin barrier and increases collagen. It is an alternative for patients who cannot tolerate retinoic acid or traditional retinol treatments. A prescription is not required, and it can be applied daily. For more information, visit www.NIA24.com.
Stelara
Janssen Biotech Inc obtains US Food and Drug Administration approval of Stelara (ustekinumab) to treat patients with active psoriatic arthritis, alone or in combination with methotrexate. Stelara targets the cytokines IL-12 and IL-23 to control joint pain, swelling, and stiffness associated with psoriatic arthritis, in addition to psoriasis plaque thickness, scaling, and redness. Stelara is administered every 12 weeks after 2 starter doses for the treatment of psoriatic arthritis. For more information, visit www.stelarainfo.com.
XTRAC Velocity 7
PhotoMedex Inc introduces XTRAC Velocity 7 with an advanced user interface for psoriasis and vitiligo. Using UVB light, the XTRAC excimer laser treats areas of the skin affected by psoriasis or vitiligo without harming the surrounding tissue. XTRAC Velocity 7 offers increased efficiency, with the rate of output increasing the speed for delivery of treatment. Treatment guidelines and suggestions based on body area are provided using the touch screen. It can be used on hard-to-reach areas such as the elbows, knees, and scalp. Before and after photographs can be stored to show progression of resolution, enhancing patient compliance. The manufacturer also offers a patient advocacy program for patients to call and obtain answers to product and insurance questions from a live operator; patients also can book appointments with a participating physician faster using the XTRAC TeleCare Center. For more information, visit www.xtracnow.com
